> Detailanzeige

Haefliger, Simon; Chervova, Olga; Davies, Christopher; Nottley, Steven; Hargreaves, Steven; Sumathi, Vaiyapuri P; Amary, Fernanda; Tirabosco, Roberto; Pillay, Nischalan; Beck, Stephan; Flanagan, Adrienne M; Lyskjær, Iben

Subclassification of epithelioid sarcoma with potential therapeutic impact

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Subclassification of epithelioid sarcoma with potential therapeutic impact
  • Beteiligte: Haefliger, Simon; Chervova, Olga; Davies, Christopher; Nottley, Steven; Hargreaves, Steven; Sumathi, Vaiyapuri P; Amary, Fernanda; Tirabosco, Roberto; Pillay, Nischalan; Beck, Stephan; Flanagan, Adrienne M; Lyskjær, Iben
  • Erschienen: Wiley, 2023
  • Erschienen in: The Journal of Pathology
  • Sprache: Englisch
  • DOI: 10.1002/path.6135
  • ISSN: 0022-3417; 1096-9896
  • Schlagwörter: Pathology and Forensic Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Epithelioid sarcoma is a rare and aggressive mesenchymal tumour, the genetic hallmark of which is the loss of expression of <jats:italic>SMARCB1</jats:italic>, a key member of the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin remodelling complex. Hampered by its rarity, epithelioid sarcoma has received little research attention and therapeutic options for this disease remain limited. <jats:italic>SMARCB1</jats:italic>‐deficient tumours also include malignant rhabdoid tumour, atypical teratoid and rhabdoid tumour, epithelioid malignant peripheral nerve sheath tumour, and poorly differentiated chordoma. Histologically, it can be challenging to distinguish epithelioid sarcoma from malignant rhabdoid tumour and other <jats:italic>SMARCB1‐</jats:italic>deficient tumours, whereas methylation profiling shows that they represent distinct entities and facilitates their classification. Methylation studies on <jats:italic>SMARCB1</jats:italic>‐deficient tumours, although not including epithelioid sarcomas, reported methylation subgroups which resulted in new clinical stratification and therapeutic approaches. In addition, emerging evidence indicates that immunotherapy, including immune checkpoint inhibitors, represents a promising therapeutic strategy for <jats:italic>SMARCB1‐</jats:italic>deficient tumours. Here, we show that some epithelioid sarcomas share methylation patterns of malignant rhabdoid tumours indicating that this could help to distinguish these entities and guide treatment. Using gene expression data, we also showed that the immune environment of epithelioid sarcoma is characterised by a predominance of CD8<jats:sup>+</jats:sup> lymphocytes and M2 macrophages. These findings have potential implications for the management of patients with epithelioid sarcoma. © 2023 The Authors. <jats:italic>The Journal of Pathology</jats:italic> published by John Wiley &amp; Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</jats:p>